UB Paderborn / Katalog / Suche / in CDI

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Gynecologic oncology, 2020-09, Vol.158 (3), p.666-672

2020

Volltextzugriff (PDF)

Cancers épithéliaux de l’ovaire et chirurgie de cytoréduction par voie mini-invasive après chimiothérapie néoadjuvante : revue systématique de la littérature

Gynécologie Obstétrique Fertilité & Sénologie, 2021-10, Vol.49 (10), p.736-743

2021

Volltextzugriff (PDF)

Insuffisance rénale aiguë et inhibiteurs de PARP

Néphrologie & thérapeutique, 2019-09, Vol.15 (5), p.356-356

2019

Volltextzugriff (PDF)

Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review

Gynécologie, obstétrique, fertilité & sénologie, 2021-10, Vol.49 (10), p.736-743

2021

Volltextzugriff (PDF)

2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

European journal of cancer (1990), 2015-09, Vol.51, p.S489-S489

2015

Volltextzugriff (PDF)

2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel

European journal of cancer (1990), 2015-09, Vol.51, p.S488-S488

2015

Volltextzugriff (PDF)

Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Annals of oncology, 2019-10, Vol.30, p.v335-v336

2019

Volltextzugriff (PDF)

859P - Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Annals of oncology, 2019-10, Vol.30, p.v335-v336

2019

Volltextzugriff (PDF)

553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the French cohort temporary authorization of use (ATU)

Annals of oncology, 2022-09, Vol.33, p.S801-S802

2022

Volltextzugriff (PDF)

544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study

Annals of oncology, 2022-09, Vol.33, p.S796

2022

Volltextzugriff (PDF)

815P Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study

Annals of oncology, 2023-10, Vol.34, p.S539-S540

2023

Volltextzugriff (PDF)

727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study

Annals of oncology, 2021-09, Vol.32, p.S731-S731

2021

Volltextzugriff (PDF)

801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma

Annals of oncology, 2021-09, Vol.32, p.S763-S763

2021

Volltextzugriff (PDF)

845P Clinical utility of monitoring TP53 mutation (TP53m) circulating tumour DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)

Annals of oncology, 2020-09, Vol.31, p.S632-S632

2020

Volltextzugriff (PDF)

Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high-grade serous ovarian cancer

Gynécologie Obstétrique Fertilité & Sénologie, 2022-05, Vol.50 (5), p.450-450

2022

Volltextzugriff (PDF)

1057 Development and validation of a machine-learning-derived RNAseq prognostic signature in endometrial cancer

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A340-A341

2021

Volltextzugriff (PDF)

236 What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A211-A212

2021

Volltextzugriff (PDF)

240 Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A213-A214

2021

Volltextzugriff (PDF)

Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort

Journal of geriatric oncology, 2021-12, Vol.12 (8), p.S7

2021

Volltextzugriff (PDF)

SIOG2021-0014 - Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort

Journal of geriatric oncology, 2021-12, Vol.12 (8), p.S7-S7

2021

Volltextzugriff (PDF)

Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study

Annals of oncology, 2016-10, Vol.27, p.vi252-vi252

2016

Volltextzugriff (PDF)

Prognostic Factors for Survival and Sequencing of Life-Extending Therapies in Metastatic Castration Resistant Prostate Cancer (Mcrpc) Patients (Pts) in Post-Docetaxel (D) Setting

Annals of oncology, 2014-09, Vol.25, p.iv273

2014

Volltextzugriff (PDF)

859PPain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

789PPROGNOSTIC FACTORS FOR SURVIVAL AND SEQUENCING OF LIFE-EXTENDING THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) IN POST-DOCETAXEL (D) SETTING

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv273-iv273

2014

Volltextzugriff (PDF)

Representation of Urban Geometry Evolution Through Space-Time Cube

2023 27th International Conference Information Visualisation (IV), 2023, p.414-419

2023

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Cancers épithéliaux de l’ovaire et chirurgie de cytoréduction par voie mini-invasive après chimiothérapie néoadjuvante : revue systématique de la littérature

Insuffisance rénale aiguë et inhibiteurs de PARP

Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review

2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel

Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

859P - Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the French cohort temporary authorization of use (ATU)

544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study

815P Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study

727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study

801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma

845P Clinical utility of monitoring TP53 mutation (TP53m) circulating tumour DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)

Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high-grade serous ovarian cancer

1057 Development and validation of a machine-learning-derived RNAseq prognostic signature in endometrial cancer

236 What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?

240 Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer

Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort

SIOG2021-0014 - Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort

Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study

Prognostic Factors for Survival and Sequencing of Life-Extending Therapies in Metastatic Castration Resistant Prostate Cancer (Mcrpc) Patients (Pts) in Post-Docetaxel (D) Setting

859PPain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

789PPROGNOSTIC FACTORS FOR SURVIVAL AND SEQUENCING OF LIFE-EXTENDING THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) IN POST-DOCETAXEL (D) SETTING

Representation of Urban Geometry Evolution Through Space-Time Cube

Suchergebnisse filtern